✨ FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
fam-trastuzumab-deruxtecan-nxki: an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer.
🌐Website: WWW.CGC2023.COM
fam-trastuzumab-deruxtecan-nxki: an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer.
🌐Website: WWW.CGC2023.COM